GLP-1 Receptor Agonists and Family History of Cancer
GLP-1 receptor agonists are generally appropriate for patients with a family history of cancer, with the critical exception of those with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), in whom these agents are absolutely contraindicated.
Absolute Contraindications
The FDA black box warning is unequivocal: GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2A or 2B 1, 2, 3. This restriction is based on preclinical rodent studies showing thyroid C-cell tumor development, though this has not been confirmed in human trials 4.
Before prescribing any GLP-1 RA, you must specifically ask about:
- Personal history of medullary thyroid cancer
- Family history of medullary thyroid cancer in any first- or second-degree relative
- Known or suspected MEN2 syndrome in the patient or family
If any of these are present, do not prescribe GLP-1 receptor agonists under any circumstances.
Other Cancer Types: Evidence of Safety
For all other cancer types, including common malignancies, the evidence is reassuring:
Differentiated Thyroid Cancer
Recent large-scale data shows no increased risk. A 2025 multisite cohort study of 98,147 GLP-1 RA users across six countries found no association with thyroid cancer risk (HR 0.81,95% CI 0.59-1.12) with median follow-up of 1.8-3.0 years 5. A 2025 meta-analysis of 48 trials with 94,245 participants confirmed GLP-1 RAs probably have little or no effect on thyroid cancer risk (OR 1.37,95% CI 0.82-2.31) 6.
Pancreatic Cancer
GLP-1 RAs are not recommended in patients at risk for pancreatic cancer based on theoretical concerns from preclinical models 1. However, clinical evidence shows no increased risk and possibly reduced risk. The 2025 meta-analysis found no effect on pancreatic cancer (OR 0.84,95% CI 0.53-1.35) 6. A 2024 Mendelian randomization study suggested potential protective effects 7.
Gastrointestinal Cancers
Evidence suggests potential benefit. The 2024 Mendelian randomization study found GLP-1 RAs associated with reduced risk of basal cell carcinoma (OR 0.92,95% CI 0.85-0.99) but increased colorectal cancer risk (OR 1.12,95% CI 1.07-1.18) 7. However, a 2025 real-world cohort study of 183,264 patients showed reduced digestive system cancer risk (HR 0.81) 8. The 2025 meta-analysis found no significant effect on colorectal cancer 6.
Breast and Gynecologic Cancers
The evidence is favorable. The 2025 meta-analysis found GLP-1 RAs probably have little or no effect on breast cancer (OR 0.95% CI 0.60-1.49), ovarian cancer, or endometrial cancer 6. The 2024 Mendelian randomization study suggested reduced breast cancer risk (OR 0.92,95% CI 0.88-0.96) 7. Emerging research even suggests potential therapeutic benefit in endometrial cancer through restoration of progesterone receptor expression 9.
Other Cancers
The 2025 meta-analysis found no increased risk for kidney cancer, liver cancer, gallbladder cancer, esophageal cancer, multiple myeloma, or meningioma 6.
Clinical Algorithm
For patients with family history of cancer:
Screen for MTC/MEN2 contraindications (ask specifically about family history of medullary thyroid cancer or MEN2)
- If present → Absolute contraindication, use alternative therapy
- If absent → Proceed to step 2
Assess for pancreatitis history
For all other family cancer histories (breast, colon, lung, prostate, etc.)
Important Caveats
The major limitation is follow-up duration. Most trials have median follow-up of only 1.8-3.0 years 5. Cancer development typically requires longer latency periods, so we cannot definitively rule out long-term risks. However, the consistent absence of signals across multiple large studies and meta-analyses is reassuring.
The theoretical concerns from rodent studies have not materialized in human populations. The C-cell tumor risk seen in rodents appears to be species-specific and has not been observed in humans despite extensive use 4, 10.
For patients with obesity and family cancer history, the metabolic benefits may actually reduce cancer risk. The 2025 real-world study showed more pronounced cancer risk reduction in patients with BMI ≥30, particularly for pancreatic and colorectal cancers 8. This likely reflects the well-established link between obesity and cancer risk.